AGIOS PHARMACEUTICALS, INC.

For the period ended Dec 31, 2025. Filed Feb 12, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 12, 2026

AGIO$31.38+6.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(In thousands, except share and per share data) Years Ended December 31:	2025	2024	2023
Revenues:
Product revenue, net	$54,028	$36,498	$26,823
Total revenue	54,028	36,498	26,823
Operating expenses
Cost of sales	$6,345	$4,165	$2,881
Research and development	339,535	301,286	295,526
Selling, general and administrative	180,280	156,784	119,903
Total operating expenses	526,160	462,235	418,310
Loss from operations	(472,132)	(425,737)	(391,487)
Gain on sale of contingent payments	—	889,136	—
Milestone payment from gain on sale of oncology business	—	200,000	—
Interest income, net	56,379	48,083	33,344
Other income, net	1,956	6,487	6,055
Net (loss) income before taxes	(413,797)	717,969	(352,088)
Income tax (benefit) expense	(1,016)	44,244	—
Net (loss) income	$(412,781)	$673,725	$(352,088)
Net (loss) income per share - basic	$(7.12)	$11.86	$(6.33)
Net (loss) income per share - diluted	$(7.12)	$11.64	$(6.33)
Weighted-average number of common shares used in computing net (loss) income per share – basic	57,972,004	56,807,415	55,651,487
Weighted-average number of common shares used in computing net (loss) income per share – diluted	57,972,004	57,889,255	55,651,487

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.